01755nas a2200361   4500000000100000008004100001260001300042653001500055653001000070653000900080653002500089653001200114653001100126653001100137653001400148653001000162653002300172653001200195653002400207653001900231653000900250653001600259100001100275700001300286700001300299700001900312245003400331856006100365300001000426490000700436520093600443022001401379       2003                            d  c2003 Sep10aAdolescent10aAdult10aAged10aCase-Control Studies10aDapsone10aFemale10aHumans10aIncidence10aIndia10aLeprostatic Agents10aleprosy10aMalaria, Falciparum10aMalaria, Vivax10aMale10aMiddle Aged1 aSaha K1 aKapoor L1 aArora VM1 aChattopadhya D00aMalaria, leprosy and dapsone.  uhttp://www.tm.mahidol.ac.th/seameo/2003_34_3/06-3050.pdf  a501-40 v343 a<p>Although the preventive action of dapsone against P. falciparum malaria was known for many years, there was no report about the incidence of P. falciparum malaria in leprosy patients treated with dapsone, especially from areas of Southeast Asia where both leprosy and malaria are endemic. Therefore, two clinic-based malaria surveys were undertaken at a gap of 12 years, comprising 506 lepromatous leprosy patients and 499 febrile nonleprosy control subjects. Both the surveys showed that the lepromatous patients treated with MDT had only P. vivax malaria (incidence comparable to the febrile nonleprosy controls) with complete freedom from P. falciparum. On the contrary, control sujects not taking any-leprosy drugs and staying with the leprosy patients at the same beggars' home, had both P. vivax and P. falciparum malaria. It is postulated that dapsone provided protection against P. falciparum among leprosy patients.</p>  a0125-1562